Barclays reaffirms its 'in-line weighted' recommendation on Fresenius Medical Care, with an adjusted price target of €38.5 to €39, citing the German dialysis specialist's latest quarterly publication.

"The turnaround is on track, with pricing and cost savings driving stronger-than-expected operating profit in the care enablement segment", the broker points out.

Weaker same-store growth was a key focus for investors and a disappointment, but is expected to be at the low end of the year", continues Barclays.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.